Back to Search Start Over

Factors associated with the clinical outcome of patients with relapsed/refractory CD19 + acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy.

Authors :
Ortiz-Maldonado V
Rives S
Español-Rego M
Alonso-Saladrigues A
Montoro M
Magnano L
Giné E
Pascal M
Díaz-Beyá M
Castella M
Català A
Faura A
Rodríguez-Lobato LG
Oliver-Caldes A
Martínez-Roca A
Rovira M
González-Navarro EA
Ortega JR
Cid J
Lozano M
Garcia-Rey E
Fernández S
Castro P
Jordan I
Villamor N
Aymerich M
Torrebadell M
Deyà À
Fernández de Larrea C
Benitez-Ribas D
Trias E
Varea S
Calvo G
Esteve J
Urbano-Ispizua A
Juan M
Delgado J
Source :
Journal for immunotherapy of cancer [J Immunother Cancer] 2021 Dec; Vol. 9 (12).
Publication Year :
2021

Abstract

Competing Interests: Competing interests: VO-M: Consultant or advisory role (Kite Gilead, Celgene, Novartis), travel grants (Kite Gilead, Celgene, Novartis, Roche, Takeda, Janssen), honoraria (Kite Gilead). SR: Consultant or advisory role (Novartis, Jazz, Shire/Servier, Amgen, Celgene/Bristol-Myers, Kite Gilead), travel grants (Novartis, Jazz, Shire/Servier, Amgen, Celgene/Bristol-Myers, Kite Gilead), honoraria (Novartis, Jazz, Shire/Servier, Amgen, Celgene/Bristol-Myers, Kite Gilead). AA-S: Consultant or advisory role (Novartis), travel grants (Novartis), honoraria (Novartis). EG: Consultant or advisory role (Kite Gilead, Janssen, Genmab), research funding (Kite Gilead, Janssen, Roche). MD-B: Consultant or advisory role (Celgene, Novartis, Jazz, Astellas). AC: Consultant or advisory role (Novartis, Celgene), travel grants (Novartis, Celgene), honoraria (Novartis, Celgene). AF: Consultant or advisory role (Novartis), travel grants (Novartis), honoraria (Novartis). LGR-L: Travel grants (Kite Gilead, Amgen, Janssen). ML: Honoraria (Grifols, Fresenius Kabi), research funding (Terumo BCT, Maco-Pharma). AM-R: Consultant or advisory role (Bristol Myers Squibb, Abbvie), travel grants (Kite Gilead, Roche, Takeda, Janssen, Abbvie), honoraria (Abbvie). EG-R: Honoraria (Novartis). PC: Consultant or advisory role (Kite Gilead, Celgene, Janssen), travel grants (Kite Gilead, MSD, Janssen). MT: Consultant or advisory role (Novartis). CFDL: Consultant or advisory role (Janssen, Celgene/Bristol-Myers, GSK), honoraria (Janssen, Celgene/Bristol-Myers, Amgen, GSK), research funding (Janssen, Celgene/Bristol-Myers, Amgen, Takeda). GC: Consultant or advisory role (Celgene, Novartis). JE: Consultant or advisory role (Abbvie, Novartis, Celgene, Astellas, Jazz, Daiichi Dankyo, Roche, Amgen, Pfizer), travel grants (Celgene, Roche, Astellas, Daiichi Dankyo), research funding (Novartis, Celgene). AU-I: Consultant or advisory role (Kite Gilead, Celgene/Bristol-Myers, Miltenyi), travel grants (Kite Gilead, Celgene/Bristol-Myers). MJ: Consultant or advisory role (Kite Gilead, Grifols), honoraria (Kite Gilead, Grifols).

Details

Language :
English
ISSN :
2051-1426
Volume :
9
Issue :
12
Database :
MEDLINE
Journal :
Journal for immunotherapy of cancer
Publication Type :
Report
Accession number :
34907029
Full Text :
https://doi.org/10.1136/jitc-2021-003644